A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Brief summary (registry, in English)

• To characterize the safety, toxicity, and tolerability of surzetoclax in combination with etentamig in biomarker-selected subjects with relapsed or refractory (R/R) Multiple Myeloma (MM) • To determine the recommended doses of surzetoclax and etentamig when given in combination in biomarker-selected subjects with R/R MM

What you commit to

• Study type: Interventional · Phase 1/2
• Planned participants: 88
• 33 sites in 9 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose multiple myeloma came back or did not respond to earlier treatment, and who have a certain marker in their cancer cells.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Multiple myeloma that came back or did not respond to treatment (relapsed or refractory), with signs of progression during or after the last treatment.

Earlier treatment

Cannot have had etentamig or any BCMA bispecific treatment before. A stem cell transplant must not be recent (see exclusions).

Biomarker or test result

Centrally tested t(11;14) positive and/or BCL2high status.

Main reasons for not taking part

• Earlier treatment with etentamig or any BCMA bispecific
• Autologous stem cell transplant within 12 weeks
• Allogeneic stem cell transplant within 6 months, or graft versus host disease symptoms after one
• Serious kidney, nerve, mental health, hormone, metabolic, immune, lung or liver disease in the last 6 months that the investigator thinks would harm the person in the study

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (33)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details